Objective To assess the 1-year continuation rates and new pregnancies following immediate versus delayed insertion of the levonorgestrel-releasing intrauterine system (LNG-IUS) after medical termination of pregnancy (MTOP) up to 20 weeks of gestation.
Introduction
Each year, termination of pregnancy (TOP) concerns over 40 million women worldwide. 1 Statistics from 2015 show that the number of TOPs in England and Wales was approximately 186 000 (16.0/1000 women aged 15-44 years), in Scotland it was 12 000 (11.6/1000 women aged 15-44 years) and in Finland it was 9400 (8.2/1000 women aged 15-49 years). [2] [3] [4] A substantial proportion, i.e. 36-45%, of the women have a history of previous TOP. [2] [3] [4] [5] Medical termination of pregnancy (MTOP) has changed the practice in recent decades, and most TOPs are now medically induced in many countries, 55-96% in the above-mentioned countries. [2] [3] [4] Trial registration www.clinicaltrials.gov Dec 13, 2012, NCT01755715 (https://clinicaltrials.gov/ct2/show/NCT01755715) Post-TOP use of long-acting reversible contraceptives, including intrauterine devices (IUD) and implants, is the most efficient means to prevent subsequent unwanted pregnancy. 6, 7 Insertion of IUD at the time of surgical TOP is both safe and effective. [8] [9] [10] [11] Furthermore, insertion of an etonogestrel-releasing implant at the time of MTOP has resulted in higher initiation and continuation rates, and lower pregnancy rates compared with delayed insertion. 12, 13 Conventionally, after MTOP, an IUD insertion takes place in a few weeks at the time of follow up or at next menstruation. However, up to half of the women do not attend the scheduled appointment.
14, 15 We recently found that if offered shortly after MTOP (2-4 weeks) as part of the TOP service the IUD uptake was 91%. 16 Provision of IUD shortly after and as a part of a TOP service also reduced the rate of subsequent TOP. 17 The shortest delay between MTOP and IUD insertion in previous studies has been approximately 1 week. 18, 19 The aim of this randomised controlled trial was to compare the 1-year continuation rates of the levonorgestrel-releasing intrauterine system (LNG-IUS) use when offered immediately (≤3 days) versus after a delay (after 2-4 weeks) following MTOP. Secondary outcomes were rates of LNG-IUS insertion, subsequent pregnancy and TOP.
Methods
This was a prospective randomised controlled trial comparing immediate (0-3 days after misoprostol) and delayed (2-4 weeks after MTOP) insertion of the LNG-IUS (Mirena â , Bayer, Turku, Finland) after MTOP. The trial was conducted at the Department of Obstetrics and Gynaecology, Helsinki University Hospital between 30 January 2013 and 31 December 2014. The Department is a tertiary referral centre, and performs more than 95% of the TOPs in the Helsinki metropolitan area.
Previously reported continuation rates of IUD use have varied from 68 to 82% when inserted at the time of surgical TOP, or quickly after medical TOP, 8, 18, 20 and from 28 to 60% when the IUD has been inserted after 2-4 weeks or more. 18, 20, 21 Calculation of the sample size was based on the assumption that at 1 year after MTOP the LNG-IUS continuation rate is 80% in the immediate insertion group and 60% in the group of delayed insertion. Assuming an a level of 0.05, the number of 109 women per group would result in 90% power. As we also wanted to assess the expulsion rates at different gestational ages in the same study population (three subgroups: ≤63, 64-84 and 84-140 days of gestation [determined by ultrasonography]) we sought to recruit a total of 300 women, i.e. 150 in both the immediate-and delayed-insertion groups (a total of 100 women to each gestational-age subgroup). A loss of follow up of 27% was permitted to maintain the power. For the group of 85-140 days, patient enrolment was interrupted after 57 women because of the slow enrolment rate.
We recruited adult women (aged ≥ 18 years) requesting medical TOP and planning the LNG-IUS for post-TOP contraception. We had three subgroups of different gestational ages; ≤63, 64-84 and 85-140 days. Exclusion criteria were structural uterine abnormality, submucosal fibroids, suspected uterine or cervical neoplasia, and acute pelvic inflammatory disease. Other contraindications for LNG-IUS, such as acute liver disease or previous breast cancer, did not exist among the women assessed for eligibility. At the time of the MTOP the participants were randomised in a 1:1 allocation ratio to immediate or delayed insertion of LNG-IUS by computer-generated list. Randomisation was accomplished by block randomisation with random block sizes of four and six, and sequentially numbered opaque envelopes were used. The personnel responsible for generating the randomisation list and sealing the envelopes did not take part in the enrolment.
All TOP-related procedures were carried out according to current Finnish national guidelines. 22 Among women randomised to the immediate insertion in the subgroup of ≤63 days of gestation, the LNG-IUS insertion occurred within 3 days (the next regular working day) of misoprostol administration, as home administration is almost always used in Finland in MTOPs performed in early pregnancy. For the other two subgroups, the women received LNG-IUS insertion before leaving the hospital. For the women randomised to delayed insertion, the LNG-IUS was inserted at the 2-to 4-week follow up. Further follow-up visits were at 3 months after LNG-IUS insertion and 1 year after MTOP. A structured follow-up form was used to collect the data at each follow-up visit.
Clinical examination and vaginal ultrasonography were performed at the 1-year visit. Continuation of intrauterine contraception, possible complications and new pregnancies were recorded at every follow-up visit. The LNG-IUS was recorded as 'expelled' when spontaneously and completely expelled from the uterus and as 'partially expelled' if any part of the LNG-IUS was visible in the cervix, or the stem of the LNG-IUS was seen to be in the cervix on ultrasonography. A new LNG-IUS was offered at no charge if the device was partially or totally expelled, and the woman was considered to continue her contraception if a new LNG-IUS was inserted. If the woman did not attend the follow up, the research nurse tried to contact her by calling or text messaging two or three times, and if contacted, a new appointment was scheduled if preferred. Women were invited to the 1-year visit even if they had not attended the 3-month visit. To minimise the dropout rate and maximise the information, the electronic patient files of the hospital district of Helsinki and Uusimaa and the Finnish Abortion Registry were reviewed for the outcomes of MTOP to complete the information from follow ups.
The primary outcome of the present study was the continuation rate of the LNG-IUS at the 1-year visit. Secondary outcomes were the rates of new pregnancies and subsequent TOPs. We performed an intention-to-treat (ITT) and per-protocol (PP) analyses for the outcomes when appropriate. The PP analysis included women who had undergone LNG-IUS insertion as planned after MTOP. Categorical data were analysed by cross tabulation and statistical significance was calculated by Fisher's exact test. Mann-Whitney U-test was used for continuous variables. All analyses were performed with IBM SPSS statistical software versions 22 and 24.
Results
A total of 267 women were randomised, 134 to the immediate-insertion group and 133 to the delayed-insertion group ( Figure 1 ). One woman decided to continue her pregnancy after randomisation, and two had suspected cervical neoplasia in Papanicoloau smear and so were excluded from the intention-to-treat analysis. One immediate and one delayed LNG-IUS insertion failed (insertion succeeded at 2-to 4-week follow up to a woman in the immediate-insertion group, and a woman in the delayedinsertion group chose another form of contraception), 20 LNG-IUS were inserted at the time of vacuum aspiration (n = 14) or after treatment of residual tissue and/or infection (n = 6). Altogether 25 women did not receive the LNG-IUS; 11 refused insertion and 14 did not attend for insertion. These women were not included in the PP analysis. Demographic characteristics of the study participants are described in Table 1 . In brief, participants were in their late 20s and most of them had a history of previous pregnancy. Half of the women smoked regularly. Demographic characteristics were similar between the study groups. Hence, randomisation resulted in no statistically significant differences between the groups.
In all, 127 (95.5%) women in the immediate-insertion group and 111 (84.7%) women in the delayed-insertion group received the LNG-IUS (risk ratio [RR] 1.13, 95% confidence interval [95% CI] 1.04-1.22, P = 0.004) ( Table 2) . LNG-IUS insertion occurred per protocol in 116 (92.1%) and 101 (91.0%) women (RR 1.01, 95% CI 0.94-1.09, P = 0.818). One-year follow-up visits were attended by 89 (66.9%) and 63 (48.1%) women in the immediate-and delayed-insertion groups (RR 1.39, 95% CI 1.12-1.72, P = 0.003), respectively (ITT analysis). The corresponding figures were 81 (69.8%) and 57 (56.4%) (RR 1.33 95% CI 1.00-1.76, P = 0.048) according to the PP analysis. Table 2 summarises the results of the study. According to the best-case scenario (LNG-IUS inserted and its use verified or status unknown at 1 year), 113 (85%) women in the immediate-insertion group and 88 (67.2%) women in the delayed-insertion group continued LNG-IUS use (RR 1.26, 95% CI 1.10-1.45, P = 0.001). In the worst-case scenario (LNG-IUS inserted and its use verified at 1-year), the numbers were 83 (62.4%) versus 52 (39.7%), (RR 1.57, 95% CI 1.23-2.02, P < 0.0001), respectively.
Primary outcome

Secondary outcomes
LNG-IUS was removed in 10 (7.5%) (immediate group) versus 15 (11.5%) (delayed group) women (RR 0.66, 95% CI 0.31-1.41, P = 0.30) ( Table 2) . LNG-IUS removals occurred because of pain and/or bleeding problems in 15 women (n = 6; immediate group, n = 9; delayed group), because of a wish for pregnancy in four women (n = 2; immediate group, n = 2; delayed group), mood deterioration (n = 2; both delayed group), acne (n = 1; immediate group), pruritus (n = 1; delayed group), and in three women the reason was unknown (n = 1; immediate group, n = 2; delayed group).
One-year expulsion rates will be reported elsewhere relative to gestational-age subgroups. 23 In brief, if considering the entire study population, during the 1-year follow-up the total LNG-IUS expulsion rate was 3 (2.3%) in the immediate-insertion group compared with 3 (2.3%) in the delayedinsertion group (RR 0.98, 95% CI 0.20-4.79, P = 1.00), and partial expulsion rates were 27 (20.3%) versus 9 (6.9%) (RR 2.95, 95% CI 1.45-6.04, P = 0.002) (ITT analysis), respectively.
Within the first year following the index MTOP, there were 22 new pregnancies; 6 (4.5%) in the immediate-insertion group and 16 (12.2%) in the delayed-insertion group (RR 0.37, 95% CI 0.15-0.91, P = 0.027). Most of these pregnancies occurred among women who did not receive the LNG-IUS (11 [50.0%]) or the LNG-IUS was removed (8 [36.4%]). Two (9.1%) women become pregnant after an unnoticed total (delayed-insertion group) or partial (immediate-insertion group) expulsion. Neither of these women attended the 3-month visit as scheduled.
Altogether 4 (3.0%) women in the immediate-insertion and 5 (3.8%) in the delayed-insertion group requested another TOP during the follow up (RR 0.79, 95% CI 0.22-2.87, P = 0.748). Two women in the immediate-insertion group failed to receive the LNG-IUS, one LNG-IUS was removed due to pain-related problems, and one was partially expelled. In the delayed-insertion group, two women did not receive the LNG-IUS, one was removed because of a desire for pregnancy, and one pregnancy followed an unrecognised LNG-IUS expulsion. One TOP was performed for a woman who received LNG-IUS, but never returned to follow ups.
Of the remaining 13 subsequent pregnancies, there were ten deliveries (one [0.8%] in the immediate-insertion and nine [6.9%] in the delayed-insertion group, RR 0.11, 95% CI 0.01-0.85, P = 0.010) and three spontaneous miscarriages (one in the immediate-insertion and two in the delayed-insertion group).
When comparing the women receiving no LNG-IUS (26 women) with those who did (238 women), the number of new pregnancies was 11 (42.3%) versus 11 (4.6%) (RR 9.15, 95% CI 4.41-19.02, P < 0.0001), and that of new TOPs was 4 (15.4%) versus 5 (2.1%) (RR 7.32, 95% CI 2.10-25.58, P = 0.007).
Discussion
Main findings
Immediate initiation of LNG-IUS contraception following MTOP resulted in both higher uptake and 1-year continuation rates compared with delayed insertion. The overall rate of a new pregnancy was lower following immediate LNG-IUS insertion compared with delayed insertion, but subsequent rates of TOP did not differ.
Strengths and limitations
This trial was strengthened by the randomised controlled setting. Even though the drop-out rate was greater than assumed and the recruitment of the second-trimester group fell short, sensitivity analysis revealed that our primary hypothesis of better 1-year continuation rates following immediate LNG-IUS insertion compared with delayed insertion was statistically significant. Revision of clinical patient files and the Finnish Abortion Registry revealed some outcomes and so increased the information on the women lost to follow up. Even if the present trial was not powered to detect differences in secondary outcomes, such as the rate of repeat TOP, we found a statistically significant decrease in the rate of subsequent pregnancy in the ITT population.
Interpretation
The continuation rate with IUD following immediate insertion at the time of surgical TOP has varied in randomised controlled trials: between 81-92% at 6 months 20,24,25 and 68-71% at 1 year. 26 In prospective cohort studies the proportions have been 78-82% at 6 months. 27, 28 In a randomised controlled trial performed after early medical TOP (≤63 days of gestation) fast-track (approximately within 1 week) IUD insertion resulted in continuation rates of 68-69% at 6 months. However, these were secondary outcomes and statistically indistinguishable compared with delayed-insertion groups. 18, 19 Our one-year continuation rates following immediate insertion are comparable to these rates: 85% in the best case and 62% in the worst case. Especially, the continuation rates in the subgroups of 64-84 days of gestation (88% best case/69% worst case) and 85-140 days of gestation (89%/56%) were significantly higher compared with the delayed-insertion group. This is important, because TOP during second trimester is a risk factor for subsequent TOP. 29 Similar removal rates between the groups suggest that the timing of LNG-IUS insertion has no effect on the longterm continuation rates of IUS use. Bleeding problems and pain were the most common reasons for removal of the LNG-IUS as also reported previously. 28, 30 The total expulsion rates were similar between the groups, but partial expulsion occurred more often in the immediateinsertion group. A prospective observational 3-month study concerning fast-track IUD insertion after early MTOP reported an expulsion rate of 4.1%. However, an additional 6.2% were found to be partially expelled by ultrasonographic examination and subsequently removed. 30 Similarly, the 6-month expulsion rates in two RCTs have been 10-12%. 18, 19 Our 1-year overall expulsion rate in the immediate-insertion group (22.6%) was higher than reported previously, mostly due to partial expulsion (20.3%). Most women who experienced partial expulsion were motivated to continue LNG-IUS contraception and underwent new LNG-IUS insertion. Hence, expulsions did not have major effect on continuation rates in this study. Moreover, cervically located LNG-IUS seems to have as good a contraceptive effect as fundally located, 26, 31 hence partial LNG-IUS expulsion may not have such a large clinical importance.
Long-term effect on prevention of unplanned pregnancies and TOPs has been shown when an IUD is provided at the time of surgical TOP, 6, 7, 27, 32 but few previous publications have reported on the long-term effects of fast-track IUD insertion following MTOP. Within 6 months following MTOP, no pregnancies occurred among women randomised to fast-track IUD insertion in the study of Shimoni et al., 18 Data are presented as median (interquartile range), or n (%).
but the difference was not statistically significant when compared with the control group. We have recently published results from RCT (in which 81% of all TOPs in the intervention group were medical) indicating that provision of cost-free IUD as part of TOP services reduced unplanned pregnancies and halved repeat TOP rate already within 1 year of follow up. 17 In the present study, even if all women were motivated to LNG-IUS contraception at the time of MTOP and access to the insertion visit was easy, 13 (10%) women in the delayed-insertion group did not attend for LNG-IUS insertion compared with one (0.8%) woman in the immediate-insertion group. When comparing the rates of subsequent pregnancy and TOP according to LNG-IUS initiation, if LNG-IUS was not inserted, women had a nine times higher risk of another pregnancy within the year. Moreover, half of the subsequent pregnancies occurred to women who did not receive LNG-IUS. Therefore, the option to immediately initiate long-acting contraception at the time of MTOP is clinically relevant. However, further research including cost-benefit studies need to be undertaken before immediate LNG-IUS insertion becomes routine practice following MTOP. In the present study we replaced the partially expelled LNG-IUS, which needs to be taken into account in further studies. Also, only LNG-IUS was provided in this study and copper-IUD may have a different profile of adverse effects and unequal cost-effectiveness. 
Conclusion
Immediate initiation of the LNG-IUS after MTOP resulted in a higher uptake and 1-year continuation rates of intrauterine contraception compared with delayed insertion. Immediate insertion of the LNG-IUS decreased the overall 1-year pregnancy rates but failed to affect the rate of subsequent TOP. Immediate initiation of intrauterine contraception could be more widely offered to women after MTOP to ensure access to effective family planning.
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